These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Surveys of the epidemiological team of the French Rheumatology Society (RESFR) on the prescription of D-penicillamine in the treatment of rheumatoid polyarthritis].
    Author: Carter H, Chevallier J, Ghoussoub K, Paolaggi JB.
    Journal: Rev Rhum Mal Osteoartic; 1986 May; 53(5):331-9. PubMed ID: 3738396.
    Abstract:
    Two surveys carried out by the Epidemiology Team of the French Rheumatology Society (RESFR) were used to assess the treatment of rheumatoid arthritis (RA) by means of D-penicillamine (DP). In the initial survey, which is described in this article, 119 rheumatologists throughout France were asked to give their opinion as to the place of DP: they use this drug in cases of severe RA, usually after gold salts and synthetic antimalarials have proved ineffective. The dosage is generally 600 mg per day, with a maximum dosage of 900 mg per day. The rheumatologists consider DP an effective treatment with good or fair clinical safety. The most frequent adverse reactions are proteinuria and skin eruptions.
    [Abstract] [Full Text] [Related] [New Search]